Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240617 · ClinicalTrials.gov registry record · Phase 3
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
A Phase 3 study of Migraine Disorders, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
- 20
- Study locations
NCT00240617 is a Phase 3 study of Migraine Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 623 participants, above the 286-participant average among 21 other Migraine Disorders trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00240617, a Phase 3 study of Migraine Disorders, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Conditions Studied
Interventions
- DRUG placebo
- DRUG sumatriptan succinate/naproxen sodium
Study Locations (20)
California
- GSK Investigational Site - Irvine
- GSK Investigational Site - Oceanside
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - South Daytona
- GSK Investigational Site - Stuart
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Decatur
- GSK Investigational Site - Rome
Alabama
- GSK Investigational Site - Anniston
- GSK Investigational Site - Tuscaloosa
Arizona
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
Arkansas
- GSK Investigational Site - Hot Springs
Colorado
- GSK Investigational Site - Boulder
Connecticut
- GSK Investigational Site - Avon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240617
The ClinicalTrials.gov registry entry for NCT00240617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 286-participant average among 21 other Migraine Disorders trials with a reported enrollment target (118% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00240617 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00240617 about?
NCT00240617 is a clinical study titled "Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks". The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
What is the current status of trial NCT00240617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2005-10. Estimated completion is 2006-06.
What conditions does trial NCT00240617 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT00240617?
The interventions under investigation include: placebo (DRUG), sumatriptan succinate/naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00240617?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00240617 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of MAP0004 in Adult Migraineurs
COMPLETED · Phase 3
-
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.